Dimethindene

Summary

Dimethindene (CHEMBL22108) is a phase-3 clinical-stage small molecule (ATC R06AB03); indicated across 2 conditions including allergic disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: R06AB03 (+1 more)
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 292.4 Da · C20H24N2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL22108
Name	Dimethindene
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	21855
ATC	R06AB03, D04AA13
Molecular formula	C20H24N2
Molecular weight	292.4
InChIKey	MVMQESMQSYOVGV-UHFFFAOYSA-N

SMILES: CC(C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C

IUPAC name: N,N-dimethyl-2-[3-(1-pyridin-2-ylethyl)-1H-inden-2-yl]ethanamine

Also known as: Dimethpyrindene, Dimetindene, Dimetindeno, Feniallerg, Forhistal, rac-dimethindene, rac-Dimethindene, DIMETHINDENE, DIMETINDENE, dimetindene

Parent form; salt/anhydrous children: CHEMBL1870768

Patent coverage: 1,539 distinct patent families (5,214 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 5,163 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 17 (assay-derived). Sample: Muscarinic acetylcholine receptor M4, Alpha-2A adrenergic receptor, Muscarinic acetylcholine receptor M5, D(1A) dopamine receptor, Muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 1A, Muscarinic acetylcholine receptor M1, Prostaglandin G/H synthase 1, Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter.

Bioactivity

ChEMBL activities: 14 potent at pChembl ≥ 5 of 19 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HRH1	9.16	Ki	0.69	nM	CHEMBL_ACT_585630
CHRM2	7.35	Ki	44.67	nM	CHEMBL_ACT_930787
CHRM2	7.11	AC50	78.4	nM	CHEMBL_ACT_25196201
CHRM3	6.72	Ki	190.6	nM	CHEMBL_ACT_930788
CHRM1	6.58	Ki	263	nM	CHEMBL_ACT_930786
CHRM4	6.39	Ki	407.4	nM	CHEMBL_ACT_930789
CHRM5	6.1	Ki	794.3	nM	CHEMBL_ACT_930790
KCNH2	5.57	AC50	2700	nM	CHEMBL_ACT_25118555
DRD1	5.19	AC50	6524	nM	CHEMBL_ACT_25115675
DRD3	5.19	AC50	6443	nM	CHEMBL_ACT_25194976
OPRM1	5.15	AC50	7042	nM	CHEMBL_ACT_25158640
CHRM1	5.12	AC50	7570	nM	CHEMBL_ACT_25210611
HTR1A	5.06	AC50	8778	nM	CHEMBL_ACT_25165489
ADRA1A	5.06	AC50	8796	nM	CHEMBL_ACT_25219249

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
allergic disease	2	MONDO:0005271	MONDO:0005271

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02094287	Not specified	COMPLETED	Placebo Effect in the Treatment of Atopic Dermatitis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).